Travere Therapeutics (NASDAQ:TVTX) CAO Sells $902,595.39 in Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sandra Calvin sold 21,977 shares of the firm’s stock in a transaction on Tuesday, April 14th. The stock was sold at an average price of $41.07, for a total value of $902,595.39. Following the sale, the chief accounting officer owned 42,353 shares in the company, valued at $1,739,437.71. This trade represents a 34.16% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sandra Calvin also recently made the following trade(s):

• On Tuesday, February 3rd, Sandra Calvin sold 4,333 shares of Travere Therapeutics stock. The stock was sold at an average price of $32.12, for a total value of $139,175.96.

Travere Therapeutics Price Performance

TVTX stock opened at $40.77 on Friday. Travere Therapeutics, Inc. has a 52-week low of $13.88 and a 52-week high of $43.31. The stock’s fifty day simple moving average is $29.99 and its 200-day simple moving average is $31.59. The company has a quick ratio of 2.70, a current ratio of 2.74 and a debt-to-equity ratio of 2.71. The stock has a market capitalization of $3.77 billion, a price-to-earnings ratio of -135.90 and a beta of 0.86.

Key Headlines Impacting Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: FDA grants full approval for Filspari in focal segmental glomerulosclerosis (FSGS), expanding Travere’s addressable U.S. patient population and underpinning multi‑year revenue upside. Filspari approval article
• Positive Sentiment: Multiple brokerages raised ratings and price targets (examples cited include Canaccord, Guggenheim, Piper Sandler and HC Wainwright), reinforcing bullish revenue and valuation revisions tied to the approval. Guggenheim note
• Neutral Sentiment: Trading and options volumes are unusually high around the approval-driven move, amplifying short‑term swings and making intraday price moves less predictive of fundamentals. Options activity report
• Neutral Sentiment: Company commentary and analyst write‑ups are clarifying label scope and launch plans but have not yet produced concrete revenue reads — useful for modeling but not definitive for near‑term earnings. Company discussion
• Negative Sentiment: Significant insider selling occurred over the last two trading days (CEO, directors, CFO, CAO and others). Most sales were via Rule 10b5‑1 plans or to cover tax withholding, but the scale of disposals can intensify near‑term downward pressure and signal profit‑taking after the approval rally. Insider trades summary
• Negative Sentiment: Some analysts caution that elevated expectations and rapid estimate revisions may limit further upside near term; the stock could consolidate or retrace as investors re‑rate forward revenue assumptions. Zacks caution

Wall Street Analyst Weigh In

Several research firms have recently issued reports on TVTX. Citigroup raised their price objective on Travere Therapeutics from $48.00 to $53.00 and gave the stock a “buy” rating in a report on Tuesday. Guggenheim increased their target price on Travere Therapeutics from $49.00 to $54.00 and gave the stock a “buy” rating in a research report on Tuesday, April 14th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Travere Therapeutics in a research report on Wednesday, January 21st. Wedbush increased their target price on Travere Therapeutics from $39.00 to $44.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 14th. Finally, Canaccord Genuity Group increased their target price on Travere Therapeutics from $47.00 to $56.00 and gave the stock a “buy” rating in a research report on Tuesday, April 14th. Eleven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $42.50.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. SG Americas Securities LLC raised its position in Travere Therapeutics by 60.4% in the first quarter. SG Americas Securities LLC now owns 54,691 shares of the company’s stock valued at $1,625,000 after purchasing an additional 20,591 shares during the period. Diversified Trust Co raised its position in Travere Therapeutics by 12.4% in the first quarter. Diversified Trust Co now owns 28,161 shares of the company’s stock valued at $837,000 after purchasing an additional 3,117 shares during the period. Rockefeller Capital Management L.P. grew its stake in shares of Travere Therapeutics by 1,604.5% during the fourth quarter. Rockefeller Capital Management L.P. now owns 2,642 shares of the company’s stock valued at $101,000 after acquiring an additional 2,487 shares in the last quarter. Mercer Global Advisors Inc. ADV acquired a new stake in shares of Travere Therapeutics during the fourth quarter valued at about $278,000. Finally, Empowered Funds LLC acquired a new stake in shares of Travere Therapeutics during the fourth quarter valued at about $115,000.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.